This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for autoinjector devices. Based on parameters, such as number of commercialized combination products, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030.
In order to provide a detailed future outlook, our projections have been segmented on the basis of:
[A] usability (disposable and reusable)
[B] route of administration (subcutaneous and intramuscular)
[C] type of molecule (monoclonal antibody, peptide, protein and small molecule)
[D] therapeutic indication (anaphylaxis, multiple sclerosis, rheumatoid arthritis, migraine, diabetes and other indications)
[E] key geographies (North America, Europe, Asia-Pacific and Rest of the World)
More than 40% of the US population is estimated to be suffering from some form of a chronic health condition. According to the US National Health Council, over 75% of the nation's healthcare expenditure is on the treatment of chronic diseases, such as diabetes. The major share of expenses incurred by patients living with a chronic disorder is driven by the frequent need to medicate, which may require repeated visits to hospitals / out-patient clinics. Over time, a variety of solutions enabling self-administration of injectable drugs have been developed and introduced into the market.
In a relatively short time period, the self-injection devices market has grown into a prominent and promising segment within the pharmaceutical industry. Autoinjectors represent one such type of device that has witnessed increased adoption among patients, especially for the treatment of emergency situations, such as anaphylactic shocks. According to developers, such devices are relatively easier to use, compared to other parenteral drug delivery systems, and have integrated needle-safety features. In fact, autoinjectors have been proven to have resolved a number of injection-related tolerability issues faced by patients.
Over the years, several players have launched proprietary autoinjectors-based combination products for use across a variety of therapeutic areas. EpiPen is one of the most popular and widely recognized autoinjectors (based on historical sales data) available in the market today. Examples of other autoinjector combination products approved in 2019 include, NUCALA Autoinjector (GlaxoSmithKline), Vyleesi Autoinjector (AMAG Pharmaceuticals / Palatin Technologies), Fasenra (AstraZeneca) and Teribone (Asahi Kasei Pharma). Autoinjectors are also considered to be a potential pharmaceutical life cycle management tool; they are used by many pharmaceutical players to expand marketing exclusivity periods of proprietary drugs.
For example, lyophilized Enbrel was reformulated for delivery via the SureClick autoinjector; this granted the drug almost 11 additional years of patent protection. It is also worth highlighting that there are a number of efforts underway to improve the existing generation of autoinjectors. Incorporation of healthcare data acquisition and analysis features, addition of smart functions to deal with medication-related errors, and improved safety measures, are some of the upgrades that device developers claim to be in the process of developing. In this context, it is worth mentioning that, so far, over 4,600 patent applications have been filed for autoinjectors and affiliated products / technologies. We believe that such efforts are likely to drive growth in this market over the coming years.
In addition to other elements, the study includes:
An overview of the current market landscape of companies engaged in developing and / or manufacturing autoinjectors, providing information on the usability (disposable and reusable), type of primary drug container (cartridge, syringe and vial), volume of container, type of dose (fixed and variable), route of administration (intradermal, intramuscular and subcutaneous), actuation mechanism (automatic and manual) and feedback mechanism integrated in the device. It also provides details on the developers, highlighting their year of establishment, company size (small-sized, mid-sized and large), location of headquarters and location of manufacturing facilities
Information on companies that are developing drugs in combination with autoinjectors, featuring details on initial year of approval (for marketed products), phase of development, usability of the device, route of administration (intracavernous, intramuscular and subcutaneous), type of drug molecule (antibody, peptide, protein and small molecule), dose strength, therapeutic area and other approved dosage forms (for marketed products). In addition, the section provides details on the company, including year of establishment, company size and location of headquarters
A competitiveness analysis of various disposable and reusable autoinjectors, taking into consideration supplier power (based on year of establishment and company size) and key product specifications, such as route of administration, primary drug container used, injector actuation mechanism, type of dose and user friendliness of the product.
An in-depth analysis of the various patents that have been filed/granted related to autoinjectors, till August 2019, highlighting details on key parameters, such as type of patent, publication year, issuing authority, CPC classification, emerging focus areas and leading industry players (on the basis of number of patents). It also includes a detailed patent benchmarking and an insightful valuation analysis.
A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as strength and diversity of product portfolio, route of administration, actuation mechanism, geographical presence / reach and supplier power of each company.
A list of marketed drugs/therapies and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future, shortlisted on the basis of an in-depth analysis that takes into consideration various relevant parameters, such as route of administration, type of drug molecule, target indications, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).
A list of key opinion leaders (KOLs) within this domain who were short-listed based on their contributions (such as involvement in clinical trials and being mentioned in patent applications); it features a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain.
Detailed case studies on the most commonly targeted indications, covering history of development and detailed description of the approved autoinjector products, along with their respective mechanisms of action and historical sales records; the study provides a list of all the drugs that are currently being delivered via autoinjectors.
A case study on the role of CMOs offering services for drug delivery devices; it features a list of service providers, highlighting the various types of services offered for different types of drug-delivery devices.
A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.
Elaborate profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios; each profile features an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent developments and an informed future outlook. Additionally, the report includes brief profiles of emerging players that have been established in the past decade.
Key Topics Covered
1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION 3.1. Chapter Overview 3.2. Types of Drug Delivery Systems 3.3. Drawbacks of Conventional Parenteral Delivery Systems 3.4. Needlestick Injuries 3.4.1. Incidence and Cost Burden 3.4.2. Prevention 188.8.131.52. Government Legislation for the Prevention of Needlestick Injuries 3.5. Emerging Trend of Self-Administration 3.5.1. Rising Burden of Chronic Diseases 3.5.2. Healthcare Cost Savings 3.5.3. Need for Immediate Treatment in Emergency Situations 3.5.4. Growth of Injectable Biologics Market 3.5.5. Addressing Key User Safety Requirements 3.6. Types of Self-Administration Devices 3.6.1. Prefilled Syringes 3.6.2. Pen-Injectors 3.6.3. Needle-Free Injectors 3.6.4. Autoinjectors 3.6.5. Large Volume Wearable Injectors 3.7. Overview of Autoinjectors 3.7.1. Components of Autoinjectors 3.7.2. Classification of Autoinjectors 184.108.40.206. On the Basis of Mechanism of Action 220.127.116.11. On the Basis of Usability 18.104.22.168. On the Basis of Type of Dose 3.7.3. Manufacturing / Packaging of Autoinjectors 3.7.4. Benefits of Autoinjectors 3.8. Regulatory Considerations 3.8.1. Medical Devices 3.8.2. Drug Device Combination Products 3.9. Future Perspectives
4. PRIMARY DRUG CONTAINERS 4.1. Chapter Overview 4.2. Types of Packaging 4.3. Introduction to Primary Drug Containers 4.3.1. Role of Primary Drug Containers 4.3.2. Types of Primary Drug Containers 22.214.171.124. Cartridges 126.96.36.199.1. Components of Cartridges 188.8.131.52.2. Types of Cartridges 184.108.40.206.2.1. Single Chamber Cartridge 220.127.116.11.2.2. Dual Chamber Cartridge 18.104.22.168.3. Cartridges Available in the Market 22.214.171.124. Syringes 126.96.36.199.1. Components 188.8.131.52.2. Types of Syringes 184.108.40.206.2.1. Based on Number of Chambers 220.127.116.11.2.2. Based on Type of Needle 18.104.22.168.3. Prefilled Syringe Systems Available in the Market 22.214.171.124.3.1. Glass Prefilled Syringes 126.96.36.199.3.2. Plastic Prefilled Syringes 188.8.131.52. Vials 184.108.40.206.1. Components 220.127.116.11.2. Vials Available in the Market 4.4. Comparison of Fabrication Materials
5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE 5.1. Chapter Overview 5.2. Autoinjectors: List of Devices 5.2.1. Analysis by Usability 5.2.2. Analysis by Type of Primary Container 5.2.3. Analysis by Volume of Container 5.2.4. Analysis by Type of Dose 5.2.5. Analysis by Route of Administration 5.2.6. Analysis by Actuation Mechanism 5.2.7. Analysis by Type of Feedback Mechanism 5.3. Autoinjectors: List of Developers 5.3.1. Analysis by Year of Establishment 5.3.2. Analysis by Company Size 5.3.3. Analysis by Geographical Location of Headquarters 5.3.4. Analysis by Geographical Location of Manufacturing Facilities
7. BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS 7.1. Scope and Methodology 7.2. Brand Positioning Matrix: Antares Pharma 7.3. Brand Positioning Matrix: BD 7.4. Brand Positioning Matrix: Elcam Drug Delivery Devices 7.5. Brand Positioning Matrix: Oval Medical Technologies 7.6. Brand Positioning Matrix: SHL Medical 7.7. Brand Positioning Matrix: Ypsomed 7.8. Brand Positioning Matrix: DALI Medical Devices
8. PATENT ANALYSIS 8.1. Chapter Overview 8.2. Scope and Methodology 8.3. Autoinjectors: Patent Analysis 8.3.1. Analysis by Publication Year 8.3.2. Analysis by Issuing Authority 8.3.3. Analysis by CPC Symbols 8.4. Emerging Focus Areas 8.5. Leading Players: Analysis by Number of Patents 8.6. Autoinjectors: Patent Benchmarking Analysis 8.6.1. Analysis by Patent Characteristics 8.6.2. Analysis by Geography 8.7. Autoinjectors: Patent Valuation Analysis
9. THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS 9.1. Chapter Overview 9.2. Autoinjector Combination Products: List of Approved Drugs 9.2.1. Analysis by Initial Year of Approval 9.2.2. Analysis by Usability 9.2.3. Analysis by Route of Administration 9.2.4. Analysis by Type of Molecule 9.2.5. Analysis by Dose Strength 9.2.6. Analysis by Therapeutic Area 9.2.7. Analysis by Other Approved Dosage Forms 9.3. Autoinjector Combination Products: List of Pipeline Drugs 9.3.1. Analysis by Phase of Development 9.3.2. Analysis by Route of Administration 9.3.3. Analysis by Type of Molecule 9.3.4. Analysis by Therapeutic Area 9.4. Autoinjector Combination Products: List of Developers 9.4.1. Analysis by Year of Establishment 9.4.2. Analysis by Company Size 9.4.3. Analysis by Location of Headquarters
10. CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS 10.1. Chapter Overview 10.2. Autoinjector-based Combination Products Available / Under Evaluation 10.3. Anaphylaxis 10.3.1. Overview and Epidemiology 10.3.2. Available Treatment Options: Adrenaline 10.3.2.1. Mechanism of Action 10.3.2.2. History of Development 10.3.3.3. Marketed Autoinjectors 10.3.3.3.1. Adrenaclick 10.3.3.3.2. Allerject / Auvi-Q (Formerly called e-cue) 10.3.3.3.3. Anapen 10.3.3.3.4. Emerade 10.3.3.3.5. EpiPen / EpiPen Jr 10.3.3.3.6. Jext 10.3.3.3.7. EpiPen / EpiPen Jr 10.3.3.4. Pipeline Autoinjectors 10.3.3.4.1. EpiQ 10.3.3.4.2. ANDIPen 10.3.3.4.3. MiniEpi 10.3.3.4.4. Zeneo Adrenaline 10.3.3.5. Other Dosage Forms 10.3.3.6. Historical Sales of Approved Products 10.4. Multiple Sclerosis 10.4.1. Overview and Epidemiology 10.4.2. Available Treatment Options: Interferon -1a and Interferon -1b 10.4.2.1. Mechanism of Action 10.4.2.2. History of Development 10.4.2.3. Interferon -1a Autoinjectors 10.4.2.3.1. Avonex Pen 10.4.2.3.2. PLEGRIDY Pen 10.4.2.3.3. Rebif Rebidose 10.4.2.3.4. RebiSmart 10.4.2.3.5. Rebiject II 10.4.2.3.6. ReciGen Physioject 10.4.2.4. Interferon -1b Autoinjectors 10.4.2.4.1. BETACONNECT 10.4.2.4.2. BETAJECT Comfort / Betacomfort 10.4.2.4.3. Betaject Lite 10.4.2.4.4. ExtaviJect 30G / ExtaviPro 30G 10.4.2.5. Other Marketed Autoinjectors 10.4.2.5.1. Cinnomer40 Physioject 10.4.2.5.2. CSYNC Autoinjector 10.4.2.5.3. WhisperJECT 10.4.2.5.4. Remurel Autoxon 10.4.2.6. Other Dosage Forms 10.4.2.7. Historical Sales of Approved Products 10.4.2.7.1. Interferon -1a 10.4.2.7.2. Interferon -1b 10.5. Migraine 10.5.1. Overview and Epidemiology 10.5.2. Available Treatment Options: Sumatriptan Succinate 10.5.2.1 History of Development 10.5.2.2 Marketed Autoinjectors 10.5.2.2.1. ALSUMA 10.5.2.2.2. IMITREX STATdose Pen 10.5.2.2.3. Zembrace SymTouch 10.5.2.2.4. Aimovig SureClick Autoinjector 10.5.2.2.5. Emgality Prefilled Pen 10.5.5. Other Dosage Forms 10.5.6. Historical Sales of Approved Products 10.6. Rheumatoid Arthritis 10.6.1. Overview and Epidemiology 10.6.2. Available Treatment Options 10.6.2.1 History of Development 10.6.2.2. Marketed Autoinjectors for Rheumatoid Arthritis 10.6.2.2.1. Actemra 10.6.2.2.2. CIMZIA AutoClicks Prefilled Pen 10.6.2.2.3. Enbrel SureClick 10.6.2.2.4. Hulio Prefilled Pen 10.6.2.2.5. HUMIRA Pen 10.6.2.2.6. ORENCIA ClickJect 10.6.2.2.7. OTREXUP 10.6.2.2.8. Rasuvo Autoinjector 10.6.2.2.9. SIMPONI SmartJect Autoinjector 10.6.2.2.10. KEVZARA Prefilled Pen 10.6.2.2.11. IMRALDI Prefilled Pen 10.6.4. Historical Sales of Approved Products
11. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS 11.1. Chapter Overview 11.2. Marketed Drug Candidates for Delivery via Autoinjectors 11.2.1. Most Likely Drug Candidates 11.2.2. Likely Drug Candidates 11.2.3. Less Likely Drug Candidates 11.2.4. Unlikely Drug Candidates 11.3. Clinical Drug Candidates for Delivery via Autoinjectors 11.3.1. Most Likely Drug Candidates 11.3.2. Likely Drug Candidates 11.3.3. Less Likely Drug Candidates 11.3.4. Unlikely Drug Candidates
12. KEY PLAYERS 12.1. Chapter Overview 12.2. Antares Pharma 12.2.1. Company Overview 12.2.2. Financial Information 12.2.3. Product Portfolio 18.104.22.168. Autoinjectors: Product Details 22.214.171.124.1. Vibex 126.96.36.199.2. QuickShot 188.8.131.52.3. BigShot 12.2.4. Key Collaborators 184.108.40.206. Teva Pharmaceutical 220.127.116.11. Ferring Pharmaceuticals 18.104.22.168. AMAG Pharmaceuticals 22.214.171.124. JCR Pharmaceuticals 126.96.36.199. Pfizer 188.8.131.52. Idorsia Pharmaceuticals 12.2.5. Recent Developments and Future Outlook 12.3 Consort Medical (Previously Bespak) 12.3.1. Company Overview 12.3.2. Financial Information 12.3.3. Technology Overview 12.3.4. Product Portfolio 184.108.40.206. Autoinjectors: Product Details 220.127.116.11.1. Syrina 18.104.22.168.2. OTS Autoinjector 22.214.171.124.3. Viscala Autoinjector 12.3.5. Key Collaborators 126.96.36.199. Aesica Pharmaceuticals 188.8.131.52. Undisclosed Global Biopharmaceutical Company 184.108.40.206. Regeneron Pharmaceuticals 12.3.6. Recent Developments and Future Outlook 12.4. DALI Medical Devices 12.4.1. Company Overview 12.4.2. Product Portfolio 220.127.116.11. Autoinjectors: Product Details 18.104.22.168.1. SAN-L 22.214.171.124.2. SAN-P 126.96.36.199.3. SAN-DV 188.8.131.52.4. SAN-DV Pro 12.4.3. Collaborations 184.108.40.206. Elcam Medical 12.4.4. Recent Developments and Future Outlook 12.5. Elcam Medical (E3D Elcam Drug Delivery Devices) 12.5.1. Company Overview 12.5.2. Product Portfolio 220.127.116.11. Autoinjectors: Product Details 18.104.22.168.1. Flexi-Q Disposable Autoinjectors 22.214.171.124.1.1. Flexi-Q PFS 126.96.36.199.1.2. Flexi-Q HV 188.8.131.52.1.3. Flexi -Q DV 184.108.40.206.2. Flexi-Q Reusable Autoinjectors 220.127.116.11.2.1. Flexi-Q mMU 18.104.22.168.2.2. Flexi-Q eMU-C / P 22.214.171.124.2.3. Flexi-Q EAI 12.5.3. Comparison of Elcam Medical Autoinjectors 12.5.4. Key Collaborators 126.96.36.199. DALI Medical Devices 12.5.5. Recent Developments and Future Outlook 12.6. Jiangsu Delfu Medical Devices 12.6.1. Company Overview 12.6.2. Financial Information 12.6.3. Product Portfolio 188.8.131.52. Autoinjectors: Overview and Specifications 184.108.40.206.1. Components of Delfu Autoinjectors 220.127.116.11.2. Applications of Delfu Autoinjectors 18.104.22.168.3. Features of Delfu Autoinjectors 22.214.171.124.4. Advantages of Delfu Autoinjectors 126.96.36.199.5. Specifications of Delfu Autoinjectors 188.8.131.52. Autoinjectors: Product Details 184.108.40.206.1. YZ-II 3mL Cartridge Digital Dose Setting GF Autoinjector 220.127.116.11.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector 18.104.22.168.3. DZ-IA Auto Injector Pen 22.214.171.124.4. Intravitreal Anti-VEGF Injections Electric Insulin Pens 126.96.36.199.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen 188.8.131.52.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors 184.108.40.206.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen 220.127.116.11.8. YZ-II 3mL* 1u Auto Injector Pen 18.104.22.168.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen 22.214.171.124.10. YZ-III Automatic Reusable Insulin Injection Pen 12.6.4. Recent Developments and Future Outlook 12.7. Oval Medical Technologies 12.7.1. Company Overview 12.7.2. Product Portfolio 126.96.36.199. Autoinjectors: Product Details 188.8.131.52.1 ArQ 184.108.40.206.2 ArQ - Bios 220.127.116.11.3 ArQ - Tempo 18.104.22.168.4 ArQ - Vita 12.7.3. Key Collaborators 22.214.171.124. SOLIZE 12.7.4. Recent Developments and Future Outlook 12.8. Owen Mumford 12.8.1. Company Overview 12.8.2. Product Portfolio 126.96.36.199. Autoinjectors: Product Details 188.8.131.52.1. Autoject Micro 184.108.40.206.2. Autoject 2 220.127.116.11.3. Autoject Mini 18.104.22.168.4. Autoject Visco 22.214.171.124.5. UniSafe Autoinjector 126.96.36.199.6. UniSafe Connected Auto-injector 12.8.3. Key Collaborators 188.8.131.52. Sanofi Aventis 12.8.4. Recent Developments and Future Outlook 12.9. SHL Group 12.9.1. Company Overview 12.9.2. Product Portfolio 184.108.40.206. Two-Step Disposable Autoinjectors: Product Details 220.127.116.11.1 Amber (Pushclick Technology) 18.104.22.168.2. Molly 22.214.171.124.3. MollyRNS 126.96.36.199.4. Molly 2.25 188.8.131.52.5. Rotaject 184.108.40.206.6. Bertha 220.127.116.11.7. DAI 2 18.104.22.168.8. Maggie 22.214.171.124.9. Comparison of SHL Two-Step Autoinjectors 126.96.36.199. Three-Step Disposable Autoinjectors: Product Details 188.8.131.52.1. DAI 184.108.40.206.2. SDI-MIX+NIT (Needle Isolation Technology and Twist and Mix Mechanism) 220.127.116.11.3. VSDI+NIT 18.104.22.168.4. Comparison of SHL Three-Step Autoinjectors 22.214.171.124.5. PPI Injector (Rotaject Pressure Release Technology) 12.9.3. Key Collaborators 126.96.36.199. Schreiner MediPharm 188.8.131.52. QuiO 12.9.4. Recent Developments and Future Outlook 12.10. Union Medico 12.10.1. Company Overview 12.10.2. Technology Overview 12.10.3. Product Portfolio 184.108.40.206. Autoinjectors: Product Details 220.127.116.11.1 45 Autoinjector 18.104.22.168.2 45/ S Autoinjector 22.214.171.124.3 45/ M Autoinjector 126.96.36.199.4 45/ R Autoinjector 188.8.131.52.5 Comparison of 45 Autoinjectors 184.108.40.206.6 90Autoinjector 220.127.116.11.7 90/ S Autoinjector 18.104.22.168.8 90/ M Autoinjector 22.214.171.124.9 90/ XL Autoinjector 126.96.36.199.10 SuperGrip Autoinjector 188.8.131.52.11 Exclusive Autoinjector 184.108.40.206.12 Comparison of 90 Autoinjectors 12.10.4. Recent Developments and Future Outlook 12.11. Ypsomed 12.11.1. Company Overview 12.11.2. Financial Information 12.11.3. Product Portfolio 220.127.116.11. Autoinjectors: Product details 18.104.22.168.1. YpsoMate, YpsoMate 2.25 and YpsoMate 2.25Pro 22.214.171.124.2. VarioJect 126.96.36.199.3. Comparison of Autoinjectors 12.11.4. Key Collaborators 188.8.131.52. I-SENS 184.108.40.206. Royal Philips 220.127.116.11. JDRF 12.11.5. Recent Developments and Future Outlook
14. KOL ANALYSIS 14.1. Chapter Overview 14.2. Methodology 14.3. KOL Analysis: Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials 14.3.1. Geographical Distribution of KOLs 14.3. KOL Analysis: Patent Assignees
16. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS 16.1. Chapter Overview 16.2. Challenges Associated with Medical Device Manufacturing 16.3. Role of CMOs in Medical Device Manufacturing 16.4. Services Offered by Medical Device CMOs 16.5. Advantages Offered by Medical Device CMOs 16.6. Risks Associated with Outsourcing to CMOs 16.7. Drug Delivery Service Providers 16.8. Concluding Remarks
17. MARKET SIZING AND OPPORTUNITY ANALYSIS 17.1. Chapter Overview 17.2. Forecast Methodology and Key Assumptions 17.3. Global Autoinjectors Market, 2020-2030 (By Value) 17.3.1. Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Value) 17.3.2. Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Value) 17.3.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Value) 17.3.4. Autoinjectors Market in North America, 2020-2030 (By Value) 17.4. Global Autoinjectors Market, 2020-2030 (By Volume) 17.5. Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Value) 17.6. Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Volume) 17.7. Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Value) 17.8. Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Volume) 17.9. Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Value) 17.10. Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Volume) 17.11. Global Autoinjectors Market for Migraine, 2020-2030 (By Value) 17.12. Global Autoinjectors Market for Migraine, 2020-2030 (By Volume) 17.13. Global Autoinjectors Market for Diabetes, 2020-2030 (By Value) 17.14. Global Autoinjectors Market for Diabetes, 2020-2030 (By Volume) 17.15. Global Autoinjectors Market for Other Indications, 2020-2030 (By Value) 17.16. Global Autoinjectors Market for Other Indications, 2020-2030 (By Volume)